The decision, which the U.S. Court of Appeals for the Third Circuit said was a close call, hinged on whether an informal ...

Opdivo (nivolumab) and Merck's (NYSE:MRK) Keytruda (pembrolizumab), two highly popular checkpoint inhibitors used in the ...

Discover Merck's groundbreaking patent on genetic markers linked to enhanced C. difficile treatment responses. Learn how personalized therapy can improve patient outcomes.

Merck's Keytruda scored two important victories in women's cancer, according to presentations Sunday at the ESMO meeting.

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Merck (MRK) and Daiichi Sankyo's (DSNKY) lung cancer drug, patritumab deruxtecan hits the primary endpoint in a Phase 3 trial ...

Recent research highlights the potential of microRNAs as cost-effective and less invasive biomarkers for early diagnosis and ...

Two new papers by a team of researchers at Boston University, the Indiana University School of Medicine and the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and the German Center for ...

Monkeys that received metformin daily showed slower age-associated brain decline than did those not given the drug.

A recent study has shown that metformin, a diabetes medication, may slow ageing in monkeys by preserving cognitive function ...

Data from the Phase 3 STELLAR trial, which tested 323 participants with PAH over six months, supported the therapy’s approval ...

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...